RAND Report Recommends Case-Control Ephedra Study Look At AE Risk
This article was originally published in The Tan Sheet
Executive Summary
A case-control study examining the risk of serious adverse events related to the use of ephedra and ephedrine alkaloid-containing dietary supplements would fill a vital gap in the current body of research on the supplement ingredient, the RAND report states
You may also be interested in...
NVE Takes First Shot At Ephedra Ban: FDA Violated DSHEA, Firm Says
NVE Pharmaceuticals is challenging FDA's ban of ephedra on the grounds the agency did not meet its burden of proving the ingredient unsafe under the Dietary Supplement Health & Education Act
NVE Takes First Shot At Ephedra Ban: FDA Violated DSHEA, Firm Says
NVE Pharmaceuticals is challenging FDA's ban of ephedra on the grounds the agency did not meet its burden of proving the ingredient unsafe under the Dietary Supplement Health & Education Act
NVE Takes First Shot At Ephedra Ban: FDA Violated DSHEA, Firm Says
NVE Pharmaceuticals is challenging FDA's ban of ephedra on the grounds the agency did not meet its burden of proving the ingredient unsafe under the Dietary Supplement Health & Education Act